Cord blood Platelet Rich Plasma derivatives for clinical applications in non-transfusion medicine

dc.contributor.authorSamarkanova, Dinara
dc.contributor.authorCox, Steven
dc.contributor.authorHernández, Diana
dc.contributor.authorRodriguez Gómez, Luciano
dc.contributor.authorCasaroli Marano, Ricardo Pedro
dc.contributor.authorMadrigal, Alejandro
dc.contributor.authorQuerol Giner, Sergi
dc.date.accessioned2021-04-22T10:16:53Z
dc.date.available2021-04-22T10:16:53Z
dc.date.issued2020-05-27
dc.date.updated2021-04-22T10:16:53Z
dc.description.abstractCord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different composition and attributes. Here we describe the molecular characteristics of these preparations and we make recommendations as to their most appropriate clinical application based on functional and immunomodulatory profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs) with all three preparations dramatically reduced the production of INFγ and the expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their activation, we propose that the likely mechanism is the high levels of soluble NKG2D ligands present in plasma. Of the three preparations we investigated, CB platelet lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all analytes measured. Based on these finding we propose that CB-PR is the most suitable raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye drops for severe ocular surface pathologies and inflammatory conditions such as corneal ulcers or severe dry eye disease, respectively.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec710209
dc.identifier.issn1664-3224
dc.identifier.pmid32536916
dc.identifier.urihttps://hdl.handle.net/2445/176622
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00942
dc.relation.ispartofFrontiers in Immunology, 2020, vol. 11, p. 942
dc.relation.urihttps://doi.org/10.3389/fimmu.2020.00942
dc.rightscc-by (c) Samarkanova, Dinara et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject.classificationSang fetal
dc.subject.classificationÚlceres
dc.subject.classificationPlaquetes sanguínies
dc.subject.otherFetal blood
dc.subject.otherUlcers
dc.subject.otherBlood platelets
dc.titleCord blood Platelet Rich Plasma derivatives for clinical applications in non-transfusion medicine
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
710209.pdf
Mida:
1.67 MB
Format:
Adobe Portable Document Format